What have we learnt from targeted anti-TNF therapy?
What have we learnt from targeted anti-TNF therapy?
复制标题
DOI：
10.1136/ard.2009.117143
复制
发表时间：
2010-01-01
影响因子：
27.4
通讯作者：
Paleolog, E.
中科院分区：
文献类型：
--
作者：
Feldmann, M.;Williams, R. O.;Paleolog, E.
抗肿瘤坏死因子（anti-TNF）治疗类风湿性关节炎患者的历史可以追溯到1992年，当时Maini和Feldmann在伦敦进行了第一次原理验证试验。对作用机制进行了相当多的研究，并深入了解了抗tnf治疗提供其益处的方式。在这篇简短的综述中，将回顾所获得的知识的某些方面和许多差距。重点将放在tnf依赖性细胞因子级联及其意义，以及潜在的新治疗方法上。最后，一个有趣的挑战：许多甚至所有未满足的临床需求是否可以通过细胞因子分析来解决？
Anti-tumour necrosis factor (anti-TNF) therapy of patients with rheumatoid arthritis dates back to 1992, when the first proof-of-principle trials were performed in London by Maini and Feldmann. Considerable studies of the mechanism of action were performed, and insights into the way in which anti-TNF therapy delivers its benefit were obtained. In this brief review, certain aspects of knowledge acquired and the many gaps will be reviewed. Focus will be on the TNF-dependent cytokine cascade and what it means, and potential new approaches to treatment. Finally, an entertaining challenge: might many or even all unmet clinical needs be dealt with through cytokine analysis?